Karyopharm Therapeutics Inc. Announces Planned Merger with Ayrmid Ltd. to Strengthen Company for the Future
– The Company Remains Focused on Supporting Patients and Advancing its Programs in Multiple Myeloma and Myelofibrosis – – Ayrmid will Serve as Lead Bidder in Court-Supervised Sale Process to Maximize Business Value for all Stakeholders – – The Company Receives a Commitment of $55 Million...